Biologics surge drives CMOs and CDMOs to boost sterile fill-finish and prefilled syringe capacity

Biologics, biosimilars and GLP-1 therapies are increasing demand for sterile injectable products, prompting contract manufacturers to expand capacity.

CMOs and CDMOs are adding fill-finish, lyophilization, inspection and packaging lines to keep up with the growing market for prefilled syringes, driven by chronic disease prevalence and self-injection trends.

At a recent conference, PCI Pharma Services disclosed a $1 billion global expansion that adds sterile fill/finish and drug-device delivery capabilities to its U.S. sites.

Industry observers say the parallel trends of device-based biologics and outpatient administration are reshaping the injectable manufacturing landscape, requiring significant infrastructure investment.